H.C. Wainwright lowered the firm’s price target on Cabaletta Bio (CABA) to $16 from $25 and keeps a Buy rating on the shares. The firm says accelerating enrollment lets rese-cel move towards registrational cohorts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA:
- Cabaletta Bio price target lowered to $2 from $3 at Wells Fargo
- Cabaletta Bio Reports Progress in Clinical Trials
- Cabaletta Bio: Strong Financial Position and Strategic Clinical Advancements Drive Buy Rating
- Cabaletta Bio’s Promising Clinical Study on CABA-201 for Myasthenia Gravis
- Cabaletta Bio files $240M mixed securities shelf